GlassScriptPhysician profile
Amanda Rae Lingerfelt
NPI 1205377876
$2,389.77
in general payments reported to CMS, 2019-2025
26 companies · $91.76 in 2025
The $91.76 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35.22 · 2021: $81.03 · 2022: $155 · 2023: $1,224 · 2024: $803 · 2025: $91.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,118.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $478.35 | 2021-2024 | |
| Glaxosmithkline, LLC. | $279.20 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $196.61 | 2022-2024 | |
| Novo Nordisk INC | $178.69 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $178.50 | 2023-2025 | |
| Amgen INC. | $132.90 | 2023-2024 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $126.69 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.99 | 2020-2024 | Ofev, Synjardy, Jardiance |
| Lilly USA, LLC | $100.09 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Daiichi Sankyo INC. | $76.32 | 2024 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.18 | 2023-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $71.88 | 2023 | Verquvo, Belsomra, Steglatro |
| Biohaven Pharmaceutical Holding Company LTD. | $58.47 | 2022 | |
| Exact Sciences Corporation | $47.17 | 2024 | Cologuard Collection Kit |
| Corium, LLC | $35.76 | 2023 | Adlarity |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $30.63 | 2023 | Veozah |
| Nevro Corp. | $29.56 | 2023 | Senza |
| Otsuka America Pharmaceutical, INC. | $28.71 | 2023-2025 | Rexulti |
| Dynavax Technologies Corporation | $25.22 | 2020-2024 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $22.79 | 2023 | Trintellix |
| Axsome Therapeutics, INC. | $22.43 | 2024 | Auvelity |
| Dexcom, INC. | $20.86 | 2024 | Dexcom G6 Transmitter |
| Philips North America LLC | $19.33 | 2024 | (Ck7) Extended Holter |
| Xeris Pharmaceuticals, INC. | $16.33 | 2025 | Gvoke Hypopen |
| Medtronic, INC. | $15.00 | 2024 | Intellis Adaptivestim |
| Exeltis, USA INC. | $13.11 | 2023 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Lingerfelt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.